RCS - Polarean Imaging PLC - Featured at 2023 ATS Respiratory Innovation Summit
03/05/2023 17:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230503:nRSC3216Ya&default-theme=true
RNS Number : 3216Y Polarean Imaging PLC 03 May 2023
Polarean Imaging Plc
(“Polarean” or the “Company”)
Featured company at 2023 ATS Respiratory Innovation Summit
Polarean also exhibiting at 2023 American Thoracic Society annual meeting,
providing a great opportunity to showcase XENOVIEW technology to other
pulmonary care innovators and providers
Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has
been selected as one of the featured companies as a poster presenter at the
American Thoracic Society's ("ATS") 2023 Respiratory Innovation Summit
("RIS"), taking place 19-20 May in Washington D.C.
The Respiratory Innovation Summit unites innovators, investors, clinicians,
and advocacy groups who work in the field of pulmonary medicine. The meeting
historically attracts more than 275 global leaders representing all facets of
the respiratory industry, including start-ups, venture capital, government,
academia, and clinicians.
In addition to Polarean being selected as a featured company, Bastiaan
Driehuys, PhD, Polarean's Chief Scientific Officer, will speak on lung imaging
as a panel member in the "Biomarkers and Innovation" session taking place in
the afternoon of 20 May at RIS.
Following the Respiratory Innovation Summit, Polarean will be exhibiting at
the 2023 ATS International Conference, taking place 21-24 May. Polarean team
members, including Bastiaan Driehuys, PhD (Chief Scientific Officer), and Alex
Dusek (Chief Commercial Officer) will be onsite to provide information on the
technology and also for networking. Polarean can be found at booth # 2137.
The ATS International Conference connects specialists in all aspects of
respiratory health - from clinicians to researchers to educators, all of whom
share a passion for improving patient care. The conference showcases the
latest advances and discoveries in respiratory science, patient care, and
global public health.
Richard Hullihen, CEO of Polarean, said: "The Respiratory Innovation Summit
and the American Thoracic Society's annual conference provide a great venue to
showcase XENOVIEW and the Xe MRI platform with individuals interested in the
opportunities to collaborate. By creating greater awareness of our Xe MRI
platform amongst clinicians, regulators, investors, and potential pharma
industry partners, these events will be another step in advancing our
commercialization strategy by growing awareness and interest in the different
ways that our technology can move pulmonary care forward."
Additionally, at ATS numerous clinicians and scientists will be presenting on
various research applications of Xe MRI. A listing of these presentations,
their title, author, and session time is available below.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Kenneth West, Chairman
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment
Banking)
Nick Adams / Nick Harland (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Anna Dunphy / Phillip Marriage Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082
RLF Communications (US media enquiries) mrash@rlfcommunications.com
Michelle Rash 336-823-5501
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the
"Group") are revenue-generating, medical imaging technology companies
operating in the high-resolution medical imaging space. Polarean aspires to
revolutionize pulmonary medicine by bringing the power and safety of MRI to
the respiratory healthcare community in need of new solutions to evaluate lung
ventilation, diagnose disease, characterize disease progression, and monitor
response to treatment. By researching, developing, and commercializing novel
imaging solutions with a non-invasive and radiation-free functional imaging
platform. Polarean's vision is to help address the global unmet medical needs
of more than 500 million patients worldwide suffering with chronic respiratory
disease. Polarean is a leader in the field of hyperpolarization science and
has successfully developed the first and only hyperpolarized MRI contrast
agent to be approved in the United States. On Dec. 23, 2022, the FDA granted
approval for Polarean's first drug device combination product, XENOVIEW(TM)
(Xenon Xe(129) hyperpolarized). Xe(129) MRI is also currently being studied
for visualization and quantification of gas exchange regionally in the
smallest airways of the lungs, across the alveolar tissue membrane, and into
the pulmonary bloodstream for future clinical indications.
About The American Thoracic Society (www.thoracic.org)
The American Thoracic Society (ATS) improves global health by advancing
research, patient care, and public health in pulmonary disease, critical
illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown
to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and
sleep apnea, among other diseases.
XENOVIEW IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.
Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.
Adverse Reactions
Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.
XENOVIEW is not approved for use in pediatric patients less than 12 years of
age.
Please see full prescribing information at www.xenoview.net
ATS Abstract Title Presentation Date Abstract Number Session and Location
129Xe Gas-exchange MRI and CT Pulmonary Vascular Abnormalities in GINA 4-5 May 21, 2023 A 1043 Mini Symposium A17.
Asthma
09:00 - 11:00
Tell me What You See: New Studies In Lung Imaging
Walter E. Washington Convention Center, Room 204 A-C (Level 2)
Hyperpolarized 129Xe MRI Visualizes Lung Function Impairment in Suspected May 21, 2023 A 1044 Mini Symposium A17.
Inflammatory Interstitial Lung Disease
09:00 - 11:00
Tell me What You See: New Studies In Lung Imaging
Walter E. Washington Convention Center, Room 204 A-C (Level 2)
Dynamic Changes in Hyperpolarized 129Xe MRI Measures After Initiation of May 21, 2023 823 Poster Discussion Session. A23.
Therapy in Patients With Idiopathic Pulmonary Fibrosis Associate With Lung
Function Poster Viewing Time
09:00 - 09:45 LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN
ILA AND ILD
Poster Discussion Time
09:45 - 11:00
Walter E. Washington Convention Center, Room 209 A-C (Level2)
Dynamic 129Xe-Hyperpolarized MRI for Non-invasive Evaluation of Regional Lung May 21, 2023 P508 Thematic Poster Session. A69.
Ventilation in Thoracic Insufficiency Syndrome
Poster Viewing Time
11:30 - 13:15 AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
Walter E. Washington Convention Center, Area E, Hall C (Lower Level)
Retrospective Cardiopulmonary Gating of Free-breathing Hyperpolarized May 21, 2023 P511 Thematic Poster Session. A69.
Xenon-129 Spectroscopy
Poster Viewing Time AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
11:30 - 13:15
Walter E. Washington Convention Center, Area E, Hall C (Lower Level)
Assessing Unilateral Lung Transplantation With Dynamic Hyperpolarized May 21, 2023 P512 Thematic Poster Session. A69.
Xenon-129
Poster Viewing Time AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
11:30 - 13:15
Walter E. Washington Convention Center, Area E, Hall C (Lower Level)
Uneven Respiratory Function Observed With Dynamic Hyperpolarized Xenon-129 MRI May 21, 2023 P513 Thematic Poster Session. A69.
in a Pig Thoracic Insufficiency Syndrome Model
Poster Viewing Time
11:30 - 13:15 AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
Walter E. Washington Convention Center, Area E, Hall C (Lower Level)
Feasibility of 3D Dynamic Gas- and Dissolved-Phase Imaging of the Rodent Lung May 21, 2023 P527 Thematic Poster Session. A69.
Using Hyperpolarized 129Xe Magnetic Resonance Imaging
Poster Viewing Time AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
11:30 - 13:15
Walter E. Washington Convention Center, Area E, Hall C (Lower Level)
Lung Structure-function in Pediatric Survivors of Congenital Diaphragmatic May 21, 2023 P528 Thematic Poster Session. A69.
Hernia
Poster Viewing Time AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
11:30 - 13:15
Walter E. Washington Convention Center, Area E, Hall C (Lower Level)
Measuring Lung Function With Inversion Instead of Saturation Recovery May 21, 2023 P529 Thematic Poster Session. A69.
Hyperpolarized Xenon-129 MR Spectroscopy
Poster Viewing Time
11:30 - 13:15 AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
Walter E. Washington Convention Center, Area E, Hall C (Lower Level)
Minimal Clinically Important Difference for 129Xe MRI Ventilation Defect May 21, 2023 P538 Thematic Poster Session. A69.
Percent in Patients With Asthma
Poster Viewing Time
11:30 - 13:15 AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
Walter E. Washington Convention Center, Area E, Hall C (Lower Level)
Hyperpolarized 129Xe Ventilation and Gas Exchange MRI in Young Adults With May 21, 2023 P539 Thematic Poster Session. A69.
Cystic Fibrosis
Poster Viewing Time
11:30 - 13:15 AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
Walter E. Washington Convention Center, Area E, Hall C (Lower Level)
Hyperpolarized 129-Xenon Magnetic Resonance Imaging (MRI) Ventilation Mapping May 22, 2023 206 RAPiD: Rapid Abstract Poster Discussion Session. B27.
in Pediatric COVID-19 Survivors
Poster Viewing Time
09:00 - 09:45 EVOLVING CONCEPTS IN LUNG FUNCTION TESTING AND MONITORING
Poster Discussion Time
09:45 - 11:00 Walter E. Washington Convention Center, Room 103 A-B (Street Level)
Tracking Regional Changes in CF Lung Disease After 1 Day of Airway-clearance May 23, 2023 Poster Discussion Session. C106.
Withdrawal, Using UTE and Xe MRI
Poster Viewing Time
14:15 - 15:00 OUT OF THE 'MUC': UPDATES IN PCD AND CF
Poster Discussion Time
15:00 - 16:15 Marriott Marquis Washington, Marquis Ballroom, Salons 3-4 (Level M2)
129Xe Magnetic Resonance Imaging-based Phenotypes of Long COVID: A May 24, 2023 602 Poster Discussion Session. D109.
Multi-center Evaluation
Poster Viewing Time
12:00 - 12:45 THE LONG AND THE SHORT OF LONG COVID
Poster Discussion Time
12:45 - 14:00 Walter E. Washington Convention Center, Room 201 (Level 2)
Post-acute COVID-19 Imaging Abnormalities on Hyperpolarized 129Xe MRI Persist May 24, 2023 610 Poster Discussion Session. D109.
Over 6 Months
Poster Viewing Time
12:00 - 12:45 THE LONG AND THE SHORT OF LONG COVID
Poster Discussion Time
12:45 - 14:00 Walter E. Washington Convention Center, Room 201 (Level 2)
Assessment of Gas Exchange in Long COVID Using Hyperpolarized 129-Xenon MRI May 23, 2023 611 Poster Discussion Session. D109.
and Dual Energy CT
Poster Viewing Time
12:00 - 12:45 THE LONG AND THE SHORT OF LONG COVID
Poster Discussion Time
12:45 - 14:00 Walter E. Washington Convention Center, Room 201 (Level 2)
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAAJMATMTTMBFJRecent news on Polarean Imaging
See all newsREG - Polarean Imaging PLC - Posting of Circular
AnnouncementREG - Polarean Imaging PLC - Result of Placing
AnnouncementREG - Polarean Imaging PLC - Proposed Placing, Subscription and Open Offer
AnnouncementREG - Polarean Imaging PLC - New Xenon MRI System order received
AnnouncementRCS - Polarean Imaging PLC - Xenon MRI to be featured at ATS 2024 conference
Announcement